![Stephen Andre](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Andre
Oficial de Recursos Humanos en CULLINAN THERAPEUTICS, INC. .
Perfil
Stephen Andre is currently the Chief Human Resources Officer at Cullinan Oncology, Inc. He previously worked as the Senior Vice President-Human Resources at Tesaro, Inc. from 2016 to 2018, Vice President-Human Resources at Panacos Pharmaceuticals, Inc., Senior Vice President-Human Resources at AMAG Pharmaceuticals, Inc., Senior Vice President-Human Resources at Synageva BioPharma Corp.
from 2012 to 2015, and Chief Human Resources Officer at Cullinan Oncology LLC.
Cargos activos de Stephen Andre
Empresas | Cargo | Inicio |
---|---|---|
CULLINAN THERAPEUTICS, INC. | Oficial de Recursos Humanos | 01/04/2022 |
Antiguos cargos conocidos de Stephen Andre.
Empresas | Cargo | Fin |
---|---|---|
TESARO INC | Oficial de Recursos Humanos | 01/04/2018 |
SYNAGEVA BIOPHARMA CORP | Oficial de Recursos Humanos | 01/01/2015 |
Cullinan Oncology LLC
![]() Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Oficial de Recursos Humanos | - |
PANACOS PHARMACEUTICALS, INC. | Oficial de Recursos Humanos | - |
AMAG PHARMACEUTICALS, INC. | Oficial de Recursos Humanos | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
PANACOS PHARMACEUTICALS, INC. | Health Technology |
CULLINAN THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 4 |
---|---|
AMAG Pharmaceuticals, Inc.
![]() AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Tesaro, Inc.
![]() Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Cullinan Oncology LLC
![]() Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
- Bolsa de valores
- Insiders
- Stephen Andre